Similar companies
Income Statement (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Revenue | 122M | 6.3% |
| Gross Profit | 67M | 10% |
| Cost of Revenue | 55M | 2% |
| Operating expense | 79M | 218% |
| Net Income | 34M | 27.2% |
Balance Sheet (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Total Assets | 558M | 9.4% |
| Total Liabilities | 160M | 16.7% |
| Total Equity | 398M | 6.7% |
| Shares Outstanding | 239M | 2.5% |
Cash Flow (USD)
| Q2 '25 | QoQ | |
|---|---|---|
| Cash from operations | 21M | 207.4% |
| Cash from financing | 48,000 | 100.7% |
EPS
Financial Highlights for ADMA Biologics in Q2 '25
ADMA Biologics reported a revenue of 122M, which is a 6.3% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 67M, marking a 10% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 55M, a 2% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 79M, showing a 218% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was 34M, showing a 27.2% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
It was a positive quarter for ADMA Biologics with growth in revenue, gross profit, and net income. Higher operating expenses might indicate increased investments or potential inefficiencies. A decline in EBITDA signals potential operational challenges or increased costs.
